Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.

摘要: Abstract Background Spasticity is a common symptom of multiple sclerosis (MS) affecting about 80% MS patients. Numerous lines evidence suggest that spasticity due to its complexity not adequately managed with conventional anti-spastic therapies. Therefore, in order improve the outcomes for majority patients, alternative approaches are needed be discovered. Over last years, use cannabinoid compounds as potential treatment MS-related symptoms has aroused great interest, owing encouraging preclinical and clinical studies. To date, Sativex, an oromucosal spray containing tetrahydrocannabinol cannabidiol approximately 1:1 ratio, only commercially available formulation cannabinoids used add-on therapy adult patients who responding antispastic Methods Here, by performing literature search, we provided overview decade evaluations well post-marketing studies effectiveness safety Sativex management spasticity. Results was proven effective treating also improving patient's quality life. In addition, low incidence adverse reactions Sativex-related supports good profile tolerability. Conclusion This review recognizing management, opened new opportunity many resistant drugs.